Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 12:00:36 14/01/26 am AEDT			5-day change	1st Jan Change
39.01 ^EUR	-1.76%		+2.28%	+5.57%

13/01	Bayer acquires two imaging markers currently in development from Attralus, Inc	RE
10/01	FluroTech Ltd. Announces Chief Financial Officer Changes	CI

Berenberg raises target for Bayer to €41 - 'Hold'

Published on 12/12/2025 at 06:15 pm AEDT - Modified on 12/12/2025 at 06:50 pm AEDT

dpa-AFX - Translated by Marketscreener - See original

Bayer AG

-1.76%

HAMBURG (dpa-AFX Broker) - Private bank Berenberg has raised its price target for Bayer from €30.40 to €41 following the company's recent strong share price performance, but has left its rating at "hold." On Friday, Sebastian Bray noted numerous positive developments at the agrochemical and pharmaceutical group that were not foreseeable at the beginning of the year. There is a high probability that the glyphosate disputes will be resolved by the end of 2026, and the chances of victory are now better. The success of the anticoagulant Asundexian in clinical trials and the relatively moderate changes in pharmaceutical prices in the US also mean that risks are minimized.

Publication of the original study: December 12, 2025 / 06:04 / GMT

First disclosure of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

-----------------------

dpa-AFX Broker – trader news from dpa-AFX

-----------------------

Latest news about Bayer AG

13/01	Bayer acquires two imaging markers currently in development from Attralus, Inc	RE
10/01	FluroTech Ltd. Announces Chief Financial Officer Changes	CI
09/01	Askbio Inc. Announces Fda Acceptance of Investigational New Drug Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease	CI
09/01	Bayer Shares Climb Further on EU Seed Policy Report	DP
09/01	FDA accepts AskBio investigational new drug for late-onset Pompe disease	RE
08/01	Drugmakers brace for Europe pricing fight after Trump's US price-cut deals	RE
08/01	Bayer Approaches Recent Highs - Report on EU Seed Policy	DP
08/01	Bayer Partners with Soufflé Therapeutics to Develop siRNA Therapy for Rare Heart Disease	MT
08/01	Bayer and Souffle Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy	CI
08/01	Bayer and Souffle Therapeutics partner up to advance cell-specific heart-targeted siRNA therapy	RE
08/01	Bayer Unit Sues Pfizer, BioNTech, Moderna for Technology Misuse in COVID-19 Vaccine Production	MT
08/01	German DAX Index Closes Higher as Eurozone Inflation Cools	MT
08/01	Bayer and Cradle Enter Collaboration to Enhance AI-Enabled Antibody Discovery and Optimization	CI
07/01	Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents	MT
07/01	Bayer Unit Sues Pfizer, BioNTech, Moderna for Technology Misuse in COVID-19 Vaccine Production	MT
07/01	Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents	MT
07/01	BAYER AG : Barclays raises its recommendation to Buy	ZD
07/01	Barclays Upgrades Bayer to 'Overweight' and Raises Target Price to 45 Euros	DP
07/01	Bayer Sues Biontech and Pfizer Over Patents for Covid Vaccines	RE
07/01	Bayer Unit Sues Pfizer, BioNTech, Moderna for Technology Misuse in COVID-19 Vaccine Production	MT
07/01	Bayer Unit Sues Pfizer, BioNTech, Moderna for Technology Misuse in COVID-19 Vaccine Production	MT
07/01	Bayer sues COVID vaccine makers over mRNA technology	RE
06/01	Bayer's Sevabertinib Lung-Cancer Drug Receives Therapy Designations in U.S., China	DJ
06/01	Bayer's Lung Cancer Drug Sevabertinib Wins Breakthrough Therapy Designations in US, China	MT
06/01	Bayer receives therapy designation for sevabertinib in US and China	RE

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

88,502

Sector

Pharmaceuticals

Calendar

06:15am - J.P. Morgan Healthcare Conference

More about the company